Joe Duffy.pdf

More documents

Recommendations

Info

uPA: ASCO Recommendation for Clinical Use • uPA may be used for the determination of prognosis in patients with newly diagnosed, node negative breast cancer. Low levels are associated with a sufficiently low risk of recurrence, especially in hormone receptor– positive women who will receive adjuvant endocrine therapy, that chemotherapy will only contribute minimal additional benefit. Harris et al. J Clin Oncol 2007;25:5287
uPA for Determining Prognosis in Breast Cancer: NACB Recommendation The NACB Panel states that testing for uPA may be carried out to identify lymph node-negative patients that do not need or are unlikely to benefit from adjuvant chemotherapy. Sturgeon et al, Clin Chem 2008;54:e11-e79
Page 1 and 2: Breast Cancer Metastasis: Biomarker
Page 3 and 4: Most Important Questions After a Di
Page 5 and 6: Node-Negative Breast Cancer: Treatm
Page 7 and 8: ADJUVANT CHEMOTHERAPY FOR BREAST CA
Page 9 and 10: QUESTION Should most node-negative
Page 11 and 12: Invasion & Metastasis Invasive Carc
Page 13 and 14: uPA in Breast Cancer • We showed
Page 15 and 16: uPA as Prognostic Markers in Breast
Page 17 and 18: LOE for Grading Clinical utility of
Page 19 and 20: Participating laboratories (9 count
Page 21 and 22: STRATIFICATION RANDOMISATION Prospe
Page 23: uPA in Breast Cancer: Implication o
Page 27: Acknowledgements • HRB • Irish

Joe Duffy.pdf

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?